Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for social cognition in schizophrenia
NCT02567032Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Oct 2010
- Primary completion
- Aug 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in schizophrenia and psychotic disorders (2 arms), sponsored by University of California, San Francisco. Primary endpoint: Change in Social Cognition Task Performance. Started Oct 2010; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
schizophreniapsychotic disorders
Beyond the preview
Go deeper on NCT02567032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567032.